Total Funding
50
39
Total FundingSeries C raised
Growth Score
-3 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
111731
Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases.
- Peter Heinecke: President and DirectorPast Role: Ionetix, General Manager, Oncology
Eric Grigsby: Chief Medical Adviser
About the Company
Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group.
The company
was established in 2009 and is based in San Francisco, California, United States.
Women Founded
